Emerging trends in gene-modified-based chimeric antigen receptor–engineered T-cellular therapy for malignant tumors: The lesson from leukemia to pediatric brain tumors

Wen Ying Lin, Yi Wei Chen, Chun Fu Lin, Yi Ping Yang, Mong Lien Wang, Kai Feng Hung, Pin I. Huang, Yi Yen Lee*, Shih Hwa Chiou

*此作品的通信作者

研究成果: Review article同行評審

2 引文 斯高帕斯(Scopus)

摘要

In 2017 and 2018, Food and Drug Administration has approved YESCARTA (axicabtagene ciloleucel) and KYMRIAH (tisagenlecleucel), two chimeric antigen receptor (CAR)-engineered T-cell products, for B-cell malignancies. It also marked a watershed moment in the development of immunotherapies for cancer. Despite the successes in adults, it remains clinically applicable only in B-cell acute lymphoblastic leukemia in pediatrics. Notably, multiple clinical trials and recent case reports about childhood central nervous system (CNS) tumors, the leading cause of deaths in children, have emerged and granted promising results. With the growing consideration of the biological responses in the interaction of human immunity, the major technical obstacles such as on-target off-tumor toxicity in widespread solid tumors, antigenic heterogeneity, adaptive resistance, difficult T-cell (CD4/CD8) trafficking, and immunosuppressive environments in CNS are gradually approached and ameliorated. The new spotlights of this review are focusing on current development, and emerging treatments for pediatric CNS tumors integrating molecular research with the mainstream of CAR-T therapeutic strategies to sketch a main axis and pathway forward in the improvement of novel gene-modified–based cellular platform.

原文English
頁(從 - 到)719-724
頁數6
期刊Journal of the Chinese Medical Association
83
發行號8
DOIs
出版狀態Published - 8月 2020

指紋

深入研究「Emerging trends in gene-modified-based chimeric antigen receptor–engineered T-cellular therapy for malignant tumors: The lesson from leukemia to pediatric brain tumors」主題。共同形成了獨特的指紋。

引用此